Rigel Pharmaceuticals Quarterly Income Statement
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rigel Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Rigel Pharmaceuticals generated $78.7 million in revenue, down 22.6% from the same quarter a year earlier. Net income was $17.3 million (-71.0% year over year), for a net margin of 22.0% versus a median of 40.2% in the prior 5 quarters. Gross margin was 89.2% (down from 95.6%) and operating margin 30.0%.
Diluted earnings per share came in at $0.88, down from $3.28.
Summary generated from market data by MetaCap's automated system. Methodology
Rigel Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 78.70M | 58.82M | 69.80M | 69.46M | 101.69M | 53.33M | 57.60M | 55.31M | 36.84M | 29.53M | 35.79M | 28.13M |
| Revenue growth (YoY) | -22.60% | +10.28% | +21.19% | +25.59% | +176.01% | +80.58% | +60.92% | +96.58% | +37.03% | +13.29% | -30.20% | +25.54% |
| Cost of Revenue | 8.53M | 4.61M | 5.96M | 4.75M | 4.50M | 4.41M | 5.79M | 8.03M | 2.81M | 2.02M | 3.79M | 1.27M |
| Gross Profit | 70.18M | 54.21M | 63.85M | 64.71M | 97.18M | 48.92M | 51.81M | 47.28M | 34.03M | 27.51M | 32.00M | 26.87M |
| Operating Expenses | 46.60M | 42.33M | 40.68M | 36.29M | 36.08M | 36.15M | 35.15M | 33.23M | 33.59M | 34.48M | 30.04M | 31.33M |
| Research & Development | 13.96M | 11.68M | — | 7.35M | 6.82M | 8.44M | 5.63M | 6.18M | 5.54M | 6.03M | 3.19M | 6.47M |
| Selling, General & Admin | 32.64M | 30.65M | 29.99M | 28.94M | 29.26M | 27.71M | 29.52M | 27.04M | 28.05M | 28.45M | 26.85M | 24.86M |
| Operating Income | 23.57M | 11.88M | 23.17M | 28.42M | 61.10M | 12.77M | 16.66M | 14.06M | 447.00K | -6.97M | 1.97M | -4.46M |
| Interest Expense | 779.00K | 1.43M | — | 1.89M | 1.87M | 1.85M | 1.96M | 2.06M | 2.03M | 1.87M | 1.91M | 1.90M |
| Pretax Income | 23.59M | 11.66M | 22.71M | 27.62M | 59.98M | 11.51M | 15.22M | 12.42M | -1.03M | -8.25M | — | — |
| Income Tax | 6.29M | 3.00M | -245.35M | -280.00K | 369.00K | 65.00K | 881.00K | 0 | 0 | 0 | — | — |
| Net Income | 17.29M | 8.65M | 268.06M | 27.90M | 59.61M | 11.45M | 14.34M | 12.42M | -1.03M | -8.25M | 737.00K | -5.69M |
| Net Income growth (YoY) | -71.00% | -24.39% | +1769.22% | +124.62% | — | — | +1845.86% | — | — | — | -47.39% | — |
| EPS (Basic) | 0.93 | 0.47 | 14.88 | 1.55 | 3.33 | 0.64 | 0.81 | 0.71 | -0.06 | -0.47 | -0.65 | -0.33 |
| EPS (Diluted) | 0.88 | 0.44 | 14.11 | 1.46 | 3.28 | 0.63 | 0.82 | 0.70 | -0.06 | -0.47 | -0.65 | -0.33 |
| Shares Outstanding (Basic) | 18.54M | 18.41M | — | 18.04M | 17.89M | 17.81M | — | 17.60M | 17.55M | 17.52M | — | 17.44M |
| Shares Outstanding (Diluted) | 19.57M | 19.69M | — | 19.16M | 18.16M | 18.17M | — | 17.65M | 17.55M | 17.52M | — | 17.44M |
| EBITDA | 24.42M | 12.48M | 23.77M | 29.02M | 61.71M | 13.38M | 17.26M | 14.67M | 1.06M | -6.57M | 2.26M | -4.17M |
| Gross Margin | 89.17% | 92.17% | 91.47% | 93.16% | 95.57% | 91.73% | 89.95% | 85.49% | 92.38% | 93.14% | 89.41% | 95.49% |
| Operating Margin | 29.95% | 20.21% | 33.19% | 40.91% | 60.09% | 23.95% | 28.92% | 25.41% | 121.00% | -23.59% | 5.49% | -15.87% |
| Net Margin | 21.97% | 14.71% | 384.04% | 40.17% | 58.63% | 21.46% | 24.90% | 22.46% | -2.80% | -27.92% | 2.06% | -20.23% |
This table shows 12 quarterly periods of Rigel Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RIGL's reporting calendar. What is a income statement?